Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Aug 12:16:1668580.
doi: 10.3389/fimmu.2025.1668580. eCollection 2025.

Editorial: Nanoparticles for cancer immunotherapy: from basics to clinics

Fernando Torres Andón  1 , Paola Allavena  2 , María José Oliveira  3 , Clement Anfray  4
Affiliations
Editorial

Editorial: Nanoparticles for cancer immunotherapy: from basics to clinics

Fernando Torres Andón et al. Front Immunol. .
No abstract available

Keywords: cancer immunotherapy; cancer resistance; combination therapy; drug delivery; nanoparticles; theragnostic nanomedicine; tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Comment on

  • Editorial on the Research Topic Nanoparticles for cancer immunotherapy: from basics to clinics

References

    1. Mellman I, Chen DS, Powles T, Turley SJ. The cancer-immunity cycle: Indication, genotype, and immunotype. Immunity. (2023) 56:2188–205. doi: 10.1016/j.immuni.2023.09.011, PMID: - DOI - PubMed
    1. Dacoba TG, Anthiya S, Berrecoso G, Fernández-Mariño I, Fernández-Varela C, Crecente-Campo J, et al. Nano-oncologicals: A tortoise trail reaching new avenues. Adv Funct Mater. (2021) 31:2009860. doi: 10.1002/adfm.202009860 - DOI
    1. Linderman SW, DeRidder L, Sanjurjo L, Foote MB, Alonso MJ, Kirtane AR, et al. Enhancing immunotherapy with tumour-responsive nanomaterials. Nat Rev Clin Oncol. (2025) 22:262–82. doi: 10.1038/s41571-025-01000-6, PMID: - DOI - PubMed
    1. Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. (2017) 14:399–416. doi: 10.1038/nrclinonc.2016.217, PMID: - DOI - PMC - PubMed
    1. Anfray C, Mainini F, Digifico E, Maeda A, Sironi M, Erreni M, et al. Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity. J Immunother Cancer. (2021) 9:e002408. doi: 10.1136/jitc-2021-002408, PMID: - DOI - PMC - PubMed

Publication types

LinkOut - more resources